miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer: The SWENOTECA-MIR Study.
Anna ThorMette Pernille MyklebustAnna Grenabo BergdahlPer-Olof LundgrenViktor SkokicBjarte AlmåsHege Sagstuen HaugnesTorgrim TandstadOlof AkreGabriella Cohn-CedermarkOlav DahlAnders KjellmanPublished in: The Journal of urology (2024)
Our study highlights miR-371a-3p as a fairly sensitive and highly specific marker for prechemotherapy seminomas, outperforming conventional markers. However, in prechemotherapy nonseminomas as well as in postchemotherapy patients, we observed low sensitivity and no significant differences in miR-371a-3p levels before and after surgery, suggesting limited utility for miR-371a-3p in this context.